Retatrutide: Eli Lilly’s GLP-1 Achieves Unprecedented Weight Loss & Knee Pain Relief
Eli Lilly's Retatrutide, a new GLP-1 drug, achieved an unprecedented 28.7% average body weight loss in trials, outperforming Zepbound. It also significantly reduced knee pain. Some side effects and dropouts were noted.